



PRESS RELEASE

PledPharma AB
Stockholm, 28 October 2020

Resolutions from extraordinary general meeting in PledPharma AB (publ) held on 28 October 2020

The extraordinary general meeting in PledPharma AB (publ) ("**PledPharma**" or the "**Company**") was held today on 28 October 2020, where the general meeting resolved in accordance with submitted proposals. The complete proposals are set out in the notice to the general meeting.

The following resolutions were among others passed at the general meeting:

Changes to the board of directors

The extraordinary general meeting resolved to elect Peder Walberg, CEO and board member in Rare Thyroid Therapeutics International AB ("**RTT**" or "**Rare Thyroid Therapeutics**"), as new board member. The general meeting's resolution regarding election of Peder Walberg as new board member is conditional upon the Company completing the acquisition of all shares in Rare Thyroid Therapeutics.

Approval of the board of directors' resolution on a share issue against payment in kind

As previously announced, PledPharma has on 5 October 2020 entered into an agreement to acquire all shares in RTT. On the same day the board of directors in PledPharma resolved, subject to the general meeting's subsequent approval, on an issue of up to 63,773,345 shares to the current shareholders of RTT against payment in kind in the form of shares in RTT. The general meeting today resolved to approve the board of directors' resolution to issue shares against payment in kind.

Approval of board of directors' resolution on new issue of shares with pre-emption rights for existing shareholders

The board of directors resolved on 5 October 2020, subject to the general meeting's subsequent approval, to issue not more than 38,238,085 shares with pre-emption rights for existing shareholders. The general meeting today resolved to approve the board of directors' resolution to issue shares.

Authorization of share issue in case of oversubscription

The general meeting resolved, in accordance with the proposal of the board of directors, to authorize the board of directors to in case of oversubscription, within thirty (30) days from the last day in the subscription period in the share issue with pre-emption rights for existing shareholders, however no later than 31 December 2020, resolve on an issue of an additional maximum of 9,523,809 shares.

For further information, please contact:

Nicklas Westerholm, CEO PledPharma
Tel. +46 (0)73 354 20 62
nicklas.westerholm@pledpharma.se

About PledPharma

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The drug candidate **Aladote**[®] is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol poisoning. A proof of principle study has been successfully completed and the design of the upcoming pivotal Phase IIb/III study for Aladote[®] has been finalized after completed interactions with FDA, EMA and MHRA. Aladote[®] has been granted Orphan Drug Designation in the US. The Phase III POLAR program for the drug candidate **PledOx**[®] was prematurely stopped in Q2 2020. Results from POLAR program will determine if further development of PledOx is warranted via strategic partnerships and is expected to be announced in Q4 2020. PledPharma (STO: PLED) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see <http://www.pledpharma.com/>